November 17, 2016 - By Nellie Frank · 0 Comments
Vermillion Inc (NASDAQ:VRML) institutional sentiment decreased to 0.4 in Q2 2016. Its down -0.20, from 0.6 in 2016Q1. The ratio is negative, as 4 institutional investors opened new or increased positions, while 10 trimmed and sold holdings in Vermillion Inc. The institutional investors in our partner’s database now possess: 19.63 million shares, down from 19.98 million shares in 2016Q1. Also, the number of institutional investors holding Vermillion Inc in their top 10 positions was flat from 1 to 1 for the same number . Sold All: 4 Reduced: 6 Increased: 3 New Position: 1.
Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The company has a market cap of $59.65 million. The Firm is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It currently has negative earnings. It sells OVA1 risk of malignancy test for pelvic mass disease .
The stock closed at $1.18 during the last session. It is down 18.62% since April 15, 2016 and is downtrending. It has underperformed by 23.24% the S&P500.
According to Zacks Investment Research, “Vermillion, Inc. is engaged in the discovery, development and commercialization of novel diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company has diagnostic programs in oncology, hematology, cardiology and women’s health. Its tests are intended to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in the selection of therapy. Vermillion also intends to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others. Its lead product includes the OVA1 ovarian tumor triage test, which addresses presurgical identification of women who are at high risk of having a malignant ovarian tumor. In addition to the OVA1 Test, Vermillion has development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease. Vermillion, Inc. is based in Fremont, California.”
Oracle Investment Management Inc holds 2.23% of its portfolio in Vermillion, Inc. for 8.62 million shares. Birchview Capital Lp owns 2.72 million shares or 2.19% of their US portfolio. Moreover, Morgens Waterfall Vintiadis & Co Inc has 1.03% invested in the company for 1.00 million shares. The New York-based Trellus Management Company Llc has invested 0.33% in the stock. Cannell Peter B & Co Inc, a New York-based fund reported 375,000 shares.#img1#
Vermillion, Inc., incorporated on May 23, 2000, is a diagnostic service and bio-analytic solutions provider. The Firm is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Firm sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). The Company’s OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. The Firm developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated.
More important recent Vermillion, Inc. (NASDAQ:VRML) news were published by: Prnewswire.com which released: “Vermillion, Inc. Kicks Off Ovarian Cancer Awareness Month by Ringing the …” on September 01, 2016, also Prnewswire.com published article titled: “Vermillion CEO to Present at Women in Bio – New York”, Prnewswire.com published: “ASPiRA LABS’ OVA1 Technology Receives “Level B” Recommendation in the Latest …” on November 09, 2016. More interesting news about Vermillion, Inc. (NASDAQ:VRML) was released by: Prnewswire.com and their article: “ASPiRA LABs Partners with New York Yankees Manager Joe Girardi for Ovarian …” with publication date: September 07, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank